Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062335 | 1.00 | DGAT1 (0.60) | DGAT1AKR1B1ESR1ESR2MAOA | |
| SCHEMBL14062088 | 0.83 | DGAT1 (0.44) | DGAT1ESR1ESR2SMN1; SMN2 | |
| SCHEMBL10341533 | 0.82 | DGAT1 (0.55) | DGAT1SMN1; SMN2 | |
| SCHEMBL10341542 | 0.81 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL14062151 | 0.81 | DGAT1 (0.62) | DGAT1AKR1B1ESR1ESR2 | |
| SCHEMBL14062083 | 0.81 | DGAT1 (0.62) | DGAT1AKR1B1ESR1ESR2 | |
| SCHEMBL14137079 | 0.81 | DGAT1 (0.69) | DGAT1 | |
| SCHEMBL3749487 | 0.80 | ESR1 (0.49) | DGAT1ESR1ESR2 | |
| SCHEMBL3411510 | 0.80 | ESR1 (0.49) | DGAT1ESR1ESR2 | |
| SCHEMBL3050076 | 0.77 | MAOA (0.50) | AKR1B1ESR1ESR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885AKR1B1 387/4885ESR1 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.